insights_auto
Kāpēc uzņēmuma ALNOV akciju cena ir samazinājusies 3,64%?
Atklājiet vairāk iespējuchevron_right
ALNOV:EPA
Novacyt SA
0,41 €
arrow_downward
-3,64%(-0,016) 1 d.
5. nov., 17:35:20 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,42 €
Augsta
0,43 €
Zema
0,41 €
Tirgus kapitalizācija
31,91 milj.
Vid. apjoms
198,56 tūkst.
Apjoms
133,90 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,42 €
Augsta
0,43 €
Zema
0,41 €
Tirgus kapitalizācija
31,91 milj.
Vid. apjoms
198,56 tūkst.
Apjoms
133,90 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
GeekWire
·
pirms 40 minūtēm
Agility Robotics co-founder on its Nasdaq debut, lessons from Amazon, and the future of work
The Motley Fool
·
pirms 34 minūtēm
The Nasdaq Plunges 5%. What the Data Center Crash Means for Investors
Alaska Story
·
pirms 14 minūtēm
Elections have consequences: Dow plunges 1,833 points as sell-off wipes out post-election rally
Fox Business
·
pirms 6 stundām
Stocks plunge as Dem midterm sweep fuels AI regulatory concerns
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
SektorsHealth Care
Industry-
Tīmekļa vietnenovacyt.com